Cancer. Encounter for antineoplastic chemotherapy
Conditions
Interventions
Intervention 1: Intervention group: Receiving desloratadine 5 mg daily for 7 days in each course of chemotherapy. Intervention 2: Control group: receiving placebo ( (Magnesium stearate, Croscarmellose
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age older than 18 years old Indication for chemotherapy Receive 1 to 3 course of chemotherapy before entry to study Occurrence bone pain with VAS score= 4 within 8 days of G-CSF derivatives injection
Exclusion criteria
Exclusion criteria: History of allergy to desloratadine or loratadine Chronic use of opioid (addiction) Chronic use of antihistamine ( more than 2 weeks during the previous month ) before entrance to study metastasis to bone Diagnosed Osteomalacia Known rheumatological disease associated with chronic bone pain Known hyperparathyroidism History of Allergy to naproxen Chronic kidney disease with GFR < 15 ml/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Daily for the first 8 days of each chemotherapy course. Method of measurement: Brief pain questionnaire, Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Beginning and at the end of therapy. Method of measurement: The European Organization for Research and Treatment of Cancer QOL Core Questionnaire 30. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAyda Esmaeili
Oroumia University of Medical Sciences
Outcome results
None listed